{"created":"2021-09-28T00:42:56.717205+00:00","id":2001440,"links":{},"metadata":{"_buckets":{"deposit":"97a5c267-c922-4003-8785-fe77157480c3"},"_deposit":{"created_by":25,"id":"2001440","owner":"25","owners":[25],"owners_ext":{"displayname":"wataka","username":"kuma1008"},"pid":{"revision_id":0,"type":"depid","value":"2001440"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:02001440","sets":["2780:1789","3:62:5298:7829"]},"author_link":["573"],"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2019-09","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"9","bibliographicPageStart":"1342","bibliographicVolumeNumber":"11","bibliographic_titles":[{"bibliographic_title":"Cancers","bibliographic_titleLang":"en"}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. In addition, drug resistance sometimes abrogates the persistent efficacy of combined therapy with BRAF and MEK inhibitors. Therefore, recent pre-clinical study-based clinical trials have attempted to identify optimal drugs (e.g., immune checkpoint inhibitors or histone deacetylase (HDAC) inhibitors) that improve the anti-melanoma effects of BRAF and MEK inhibitors. In addition, the development of novel protocols to avoid resistance of BRAF inhibitors is another purpose of recent pre-clinical and early clinical trials. This review focuses on pre-clinical studies and early to phase III clinical trials to discuss the development of combined therapy based on BRAF inhibitors for BRAF-mutant advanced melanoma, as well as mechanisms of resistance to BRAF inhibitors.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"MDPI","subitem_publisher_language":"en"}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"31514399","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.3390/cancers11091342","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).","subitem_rights_language":"en"}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"publisher"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"2072-6694","subitem_source_identifier_type":"EISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Fujimura, Taku","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"藤澤, 康弘","creatorNameLang":"ja"},{"creatorName":"フジサワ, ヤスヒロ","creatorNameLang":"ja-Kana"},{"creatorName":"FUJISAWA, Yasuhiro","creatorNameLang":"en"}],"familyNames":[{},{},{}],"givenNames":[{},{},{}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Kambayashi, Yumi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Aiba, Setsuya","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-09-28"}],"displaytype":"detail","filename":"Cancers_11-9.pdf","filesize":[{"value":"548 KB"}],"format":"application/pdf","licensetype":"license_0","url":{"objectType":"fulltext","url":"https://tsukuba.repo.nii.ac.jp/record/2001440/files/Cancers_11-9.pdf"},"version_id":"87f292d9-4f67-4ac6-b45b-5be2294dbe7d"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside","subitem_title_language":"en"}]},"item_type_id":"5","owner":"25","path":["1789","7829"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-09-28"},"publish_date":"2021-09-28","publish_status":"0","recid":"2001440","relation_version_is_last":true,"title":["Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside"],"weko_creator_id":"25","weko_shared_id":-1},"updated":"2022-04-27T10:53:36.365713+00:00"}